- Home
- NLSP vs XFOR Comparison
NLSP vs XFOR Comparison
Compare NLSP & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- XFOR
- Stock Information
- Founded
- NLSP 2015
- XFOR 2014
- Country
- NLSP Switzerland
- XFOR United States
- Employees
- NLSP N/A
- XFOR 143
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NLSP Health Care
- XFOR Health Care
- Exchange
- NLSP Nasdaq
- XFOR Nasdaq
- Market Cap
- NLSP 12.4M
- XFOR 84.3M
- IPO Year
- NLSP 2021
- XFOR N/A
- Fundamental
- Price
- NLSP $2.07
- XFOR $3.13
- Analyst Decision
- NLSP
- XFOR Strong Buy
- Analyst Count
- NLSP 0
- XFOR 3
- Target Price
- NLSP N/A
- XFOR $34.17
- AVG Volume (30 Days)
- NLSP 179.9K
- XFOR 10.6M
- Earning Date
- NLSP 10-17-2025
- XFOR 08-08-2025
- Dividend Yield
- NLSP N/A
- XFOR N/A
- EPS Growth
- NLSP N/A
- XFOR N/A
- EPS
- NLSP N/A
- XFOR N/A
- Revenue
- NLSP N/A
- XFOR $32,774,000.00
- Revenue This Year
- NLSP N/A
- XFOR $1,313.84
- Revenue Next Year
- NLSP N/A
- XFOR N/A
- P/E Ratio
- NLSP N/A
- XFOR N/A
- Revenue Growth
- NLSP N/A
- XFOR 5721.31
- 52 Week Low
- NLSP $1.30
- XFOR $1.35
- 52 Week High
- NLSP $6.97
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- NLSP 42.25
- XFOR 56.01
- Support Level
- NLSP $2.03
- XFOR $3.28
- Resistance Level
- NLSP $2.29
- XFOR $4.83
- Average True Range (ATR)
- NLSP 0.18
- XFOR 0.58
- MACD
- NLSP -0.06
- XFOR 0.02
- Stochastic Oscillator
- NLSP 3.88
- XFOR 39.92
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.